Last-Resort vaccine shows promise for deadly brain cancer
NCT ID NCT04802447
First seen Sep 30, 2025 · Last updated May 10, 2026 · Updated 29 times
Summary
This program offers SurVaxM, an experimental vaccine, to glioblastoma patients who have no other treatment options or who previously benefited from it in a trial. Early data suggest SurVaxM may help extend survival when used alone or with chemotherapy. The goal is to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.